Sertraline

"Sertraline" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A selective serotonin uptake inhibitor that is used in the treatment of depression.

Descriptor ID	D020280
MeSH Number(s)	D02.092.705.800 D02.455.426.559.847.638.845.800 D04.615.638.845.800
Concept/Terms	Sertraline Sertraline Zoloft Zoloft Altruline Lustral Apo-Sertraline Apo-Sertraline Apo Sertraline Aremis Aremis Besitran Sealdin Sealdin Gladem Gladem Novo-Sertraline Novo-Sertraline Novo Sertraline ratio-Sertraline ratio-Sertraline ratio Sertraline Rhoxal-sertraline Rhoxal-sertraline Rhoxal sertraline Sertraline Hydrochloride Sertraline Hydrochloride Hydrochloride, Sertraline Sertraline Hydrochloride (1S-cis)-Isomer Gen-Sertraline Gen-Sertraline Gen Sertraline

Below are MeSH descriptors whose meaning is more general than "Sertraline".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amines [D02.092]
1-Naphthylamine [D02.092.705]
Sertraline [D02.092.705.800]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Polycyclic Aromatic Hydrocarbons [D02.455.426.559.847]
Naphthalenes [D02.455.426.559.847.638]
1-Naphthylamine [D02.455.426.559.847.638.845]
Sertraline [D02.455.426.559.847.638.845.800]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Naphthalenes [D04.615.638]
1-Naphthylamine [D04.615.638.845]
Sertraline [D04.615.638.845.800]

Below are MeSH descriptors whose meaning is related to "Sertraline".

Below are MeSH descriptors whose meaning is more specific than "Sertraline".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Sertraline" by people in this website by year, and whether "Sertraline" was a major or minor topic of these publications.

Bar chart showing 39 publications over 24 distinct years, with a maximum of 5 publications in 2006

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	0	1	1
1994	0	1	1
1995	0	3	3
1996	0	2	2
1997	0	1	1
1998	0	2	2
2000	1	0	1
2001	2	0	2
2002	1	0	1
2003	2	1	3
2004	4	0	4
2005	1	0	1
2006	5	0	5
2008	1	0	1
2009	1	0	1
2010	2	0	2
2011	1	0	1
2012	1	0	1
2014	1	0	1
2016	0	1	1
2018	1	0	1
2019	0	1	1
2020	0	1	1
2021	1	0	1

Below are the most recent publications written about "Sertraline" by people in Profiles.

Zuschlag ZD, Leventhal KC. Rapid and Sustained Resolution of Misophonia-Type Hyperacusis With the Selective Serotonin Reuptake Inhibitor Sertraline. Prim Care Companion CNS Disord. 2021 Apr 29; 23(3).

View in: PubMed
Rauch SAM, King A, Kim HM, Powell C, Rajaram N, Venners M, Simon NM, Hamner M, Liberzon I. Cortisol awakening response in PTSD treatment: Predictor or mechanism of change. Psychoneuroendocrinology. 2020 08; 118:104714.

View in: PubMed
Hamner MB, Hernandez-Tejada MA, Zuschlag ZD, Agbor-Tabi D, Huber M, Wang Z. Ziprasidone Augmentation of SSRI Antidepressants in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Pilot Study of Augmentation Therapy. J Clin Psychopharmacol. 2019 Mar/Apr; 39(2):153-157.

View in: PubMed
Howie RN, Herberg S, Durham E, Grey Z, Bennfors G, Elsalanty M, LaRue AC, Hill WD, Cray JJ. Selective serotonin re-uptake inhibitor sertraline inhibits bone healing in a calvarial defect model. Int J Oral Sci. 2018 09 03; 10(3):25.

View in: PubMed
Richards C, McIntyre RS, Weisler R, Sambunaris A, Brawman-Mintzer O, Gao J, Geibel B, Dauphin M, Madhoo M. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Affect Disord. 2016 Dec; 206:151-160.

View in: PubMed
Flynn Longmire CV, Drye LT, Frangakis CE, Martin BK, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG. Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. Am J Geriatr Psychiatry. 2014 Jan; 22(1):14-24.

View in: PubMed
Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry. 2012 Dec; 20(12):1036-44.

View in: PubMed
Peters ME, Vaidya V, Drye LT, Rosenberg PB, Martin BK, Porsteinsson AP, Frangakis CE, Mintzer J, Weintraub D, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, Avramopoulos D, Dimitri A. Sertraline for the treatment of depression in Alzheimer disease: genetic influences. J Geriatr Psychiatry Neurol. 2011 Dec; 24(4):222-8.

View in: PubMed
Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010 Apr; 18(4):332-40.

View in: PubMed
Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010 Feb; 18(2):136-45.

View in: PubMed

People

Explore

Similar Concepts

Top Journals